Atrial Fibrillation Market: A Detailed Analysis of Market Size, Regional Dynamics, and Investment Opportunities
The Atrial Fibrillation (AF) market has been witnessing significant growth due to the rising prevalence of atrial fibrillation, a common heart rhythm disorder characterized by irregular and often rapid heartbeat. A key aspect of managing AF is early and accurate diagnosis, making Atrial Fibrillation diagnosis a crucial component in the overall market landscape.
The Atrial
fibrillation market is projected
to grow from USD 1.91 Billion in 2024 to USD 3.6 billion by 2032, exhibiting a
compound annual growth rate (CAGR) of 8.24% during the forecast period (2024 -
2032). Atrial Fibrillation, often abbreviated as AF,
refers to an irregular and chaotic beating of the heart's upper chambers,
leading to an increased risk of stroke and other cardiovascular complications.
The global Atrial Fibrillation market is expanding as the aging population and
lifestyle factors contribute to the increasing incidence of this condition.
A crucial driver of market growth is the continuous
advancement in diagnostic technologies. Innovations in electrocardiography
(ECG) machines, wearable devices, and remote monitoring systems enable
healthcare professionals to detect and diagnose atrial fibrillation more
efficiently. Additionally, the growing awareness among patients and healthcare
providers about the importance of early diagnosis has led to an increased
demand for diagnostic tools and services.
The Atrial
Fibrillation diagnosis market
encompasses a spectrum of approaches, including traditional ECGs, Holter
monitors, event monitors, and emerging technologies like mobile health
applications and smartwatches equipped with ECG capabilities. These diagnostic
tools empower individuals to monitor their heart rhythm and provide valuable
data to healthcare professionals for timely intervention.
Major Key
Players:
Some of the Atrial Fibrillation Companies are
Medtronic Plc, Johnson & Johnson Services, Inc., Abbott, Boston Scientific
Corporation, MicroPort Scientific Corporation, Biotronik SE & Co. KG,
Koninklijke Philips N.V., AtriCure, Inc., CardioFocus, Osypka AG, Siemens AG,
Biosense Webster, Inc., Sichuan Jinjiang Electronic Science and Technology Co.,
Ltd., CathRx Ltd., and Vanguard AG.
Segment Analysis
The global atrial fibrillation market has been
segmented into type, treatment, and end-user.
The atrial fibrillation devices market, on the basis
of type, has been segmented into paroxysmal atrial fibrillation, persistent
atrial fibrillation, and permanent atrial fibrillation.
The permanent type of atrial fibrillation is
anticipated to hold the largest share as it is the most common type of AFib
with a high occurrence rate. The persistent atrial fibrillation segment is
estimated to be the fastest growing owing to increased recurrence rates in
patients.
The market, on the basis of treatment, has been
segmented into medications, non-surgical procedures, and surgical procedures.
The market, based on medications, has been segmented
blood thinners, rate controllers, and rhythm controllers.
The market, based on non-surgical procedures, has
been segmented into electrical cardioversion and catheter ablation.
The market, based on surgical procedures, has been
segmented into pacemaker implantation and open-heart maze procedure.
Regional Analysis
The market in the Americas is
expected to dominate the global atrial fibrillation market during the forecast
period due to the escalation in the adoption of advanced technologies and
procedures for the treatment of atrial fibrillation, and well-developed
healthcare infrastructure. According to the Centers for Disease Control and Prevention
in 2017, an estimated 2.7–6.1 million people in the United States have atrial
fibrillation (AFib). The European market is expected to be the second-largest
due to government funding and support of the healthcare sector. Also, many
companies are setting up their research and development centers in this region,
which will boost the market growth in this region. Moreover, the market in
Asia-Pacific is anticipated to be the fastest-growing during the assessment
period owing to growing disposable income, and huge population susceptible to
cardiovascular diseases. The market in the Middle East & Africa is likely
to account for the smallest share of the global atrial fibrillation market.
Recent
Development
November 2023: In patients with atrial fibrillation with
rapid ventricular rate (AFib-RVR), etripamil nasal spray demonstrated rapid and
statistically superior ventricular rate reduction and improved symptom relief
compared to placebo, according to positive Phase 2 data released today by Milestone
Pharmaceuticals Inc. The safety and tolerability findings from the safety
population consisting of 56 patients are comparable to those reported in
Milestone's Phase 3 paroxysmal supraventricular tachycardia (PSVT) program,
which is significantly larger in scale. Concurrently with their Featured
Science presentation at the American Heart Association (AHA) Scientific
Sessions 2023 and publication in Circulation: Arrhythmia and Electrophysiology,
the findings were unveiled. Further development of self-administered etripamil
for the treatment of AFib-RVR is supported by these findings.
November 2023: During a Late-Breaking session of the
American Heart Association (AHA) meeting in November 2023, Anthos Therapeutics,
Inc., a clinical stage company established by Blackstone Life Sciences and
focused on developing novel therapies for cardiovascular diseases, disclosed
that abelacimab exhibited a substantially reduced occurrence of bleeding events
across all primary and secondary endpoints when compared to a direct-oral
anticoagulant (DOAC), which is the standard of care.
Browse Related Reports:
Digital Radiology Devices Market
Non-Alcoholic Steatohepatitis Biomarkers Market
For More
Information, Please Visit @ Market
Research Future
Comments
Post a Comment